GlassScriptPhysician profile
Costantine Albany
NPI 1427381607
$211,809.57
in general payments reported to CMS, 2019-2025
55 companies · $716 in 2025
The $716 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $43K · 2021: $83K · 2022: $23K · 2023: $4,486 · 2024: $461 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038 · Consulting Fee: $2,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.06 |
| Consulting Fee | $2,625.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $98,399.98 | 2019-2023 | |
| Seagen INC. | $44,527.02 | 2020-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $33,221.39 | 2019-2024 | Calquence, Lynparza, Enhertu |
| Astellas Pharma US INC | $24,812.84 | 2019-2025 | Padcev, Xospata, Xtandi |
| Emd Serono, INC. | $3,900.00 | 2021 | |
| Beigene USA, INC. | $2,669.33 | 2023-2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $1,177.78 | 2020-2024 | Keytruda |
| Abbvie INC. | $293.07 | 2022-2025 | Venclexta |
| Janssen Biotech, INC. | $227.93 | 2019-2023 | Darzalex, Imbruvica, Erleada |
| Celgene Corporation | $211.48 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $181.00 | 2022-2025 | Opdivo |
| Pfizer INC. | $159.46 | 2022-2025 | |
| Tempus Ai, INC | $156.90 | 2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $155.24 | 2022-2025 | |
| Incyte Corporation | $145.54 | 2022-2025 | Jakafi, Zynyz |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $138.79 | 2021-2024 | Trodelvy |
| Daiichi Sankyo INC. | $108.18 | 2023-2024 | Injectafer, Enhertu |
| Eisai INC. | $104.91 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $88.68 | 2023 | Yonsa, Odomzo |
| Exelixis INC. | $88.47 | 2020-2024 | Cabometyx |
| Amgen INC. | $84.95 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Puma Biotechnology, INC. | $65.89 | 2022-2025 | |
| Lilly USA, LLC | $58.82 | 2019-2023 | Verzenio, Retevmo, Jaypirca |
| Glaxosmithkline, LLC. | $54.95 | 2022-2025 | Zejula |
| Jazz Pharmaceuticals INC. | $51.46 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $49.56 | 2023 | Rybrevant |
| Tersera Therapeutics LLC | $44.92 | 2023 | Quzyttir |
| Cti Biopharma Corp. | $43.02 | 2023 | Vonjo |
| Regeneron Healthcare Solutions, INC. | $41.83 | 2019-2023 | Libtayo |
| Coherus Oncology, INC. | $39.44 | 2023 | |
| Genmab U.S., INC. | $38.97 | 2023-2025 | Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $36.67 | 2023 | |
| Genentech USA, INC. | $35.40 | 2023-2024 | Rozlytrek, Tecentriq, Alecensa |
| Geron Corporation | $28.97 | 2025 | Rytelo |
| Octapharma USA, INC. | $28.79 | 2024 | Octagam Immune Globulin (Human) |
| Array Biopharma INC | $27.01 | 2023 | Lorbrena, Mektovi, Xalkori |
| Aveo Pharmaceuticals, INC. | $22.52 | 2023 | Fotivda |
| Alexion Pharmaceuticals, INC. | $22.20 | 2024 | Ultomiris |
| Adma Biomanufacturing LLC | $21.58 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $21.37 | 2023 | Imbruvica |
| Verastem, INC. | $20.73 | 2019 | |
| Pharmaessentia USA Corporation | $19.91 | 2023 | Besremi |
| Ipsen Biopharmaceuticals, INC | $19.29 | 2025 | Onivyde |
| Eagle Pharmaceuticals, INC. | $18.63 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.44 | 2022 | |
| Stemline Therapeutics INC. | $18.19 | 2023 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.97 | 2019 | |
| Morphosys, US INC. | $17.55 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $16.31 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.77 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.32 | 2019 | |
| Immunogen, INC. | $13.59 | 2023 | Elahere |
| Novocure INC. | $12.56 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Costantine Albany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.